Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a
very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding …

Background In the past years, there has been a notable increase in interest regarding
targeted alpha therapy using Ac-225, driven by the observed promising clinical anti-tumor …

Purpose The β¯-emitting terbium-161 also emits conversion and Auger electrons, which are
believed to be effective in killing single cancer cells. Terbium-161 was applied with …

The widespread use of peptide receptor radionuclide therapy (PRRT) represents a major
therapeutic breakthrough in nuclear medicine, particularly since the introduction of 177Lu …

Small cell lung cancer (SCLC) is a neuroendocrine tumor with a high degree of malignancy.
Due to limited treatment options, patients with SCLC have a poor prognosis. We have found …

Existing anticancer therapeutic modalities in clinical settings lack efficacy and fail to
completely cure cancers. Clearly understandable and mechanistic approaches are …

The application of prostate-specific membrane antigen (PSMA)–targeted α-therapy is a
promising alternative to β−-particle–based treatments. 211At is among the potential α …

Neuroendocrine tumors (NETs) express somatostatin receptors (SSTRs) 2 and 5. Modified
variants of somatostatin, the cognate ligand for SSTR2 and SSTR5, are used in treatment for …

The field of radioligand therapy has advanced greatly in recent years, driven largely by β-
emitting therapies targeting somatostatin receptor–expressing tumors and the prostate …

Abstract Background The [177Lu] Lu-DOTA-TATE mediated peptide receptor radionuclide
therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment …